NewsBenzingaInformado el domingo, Viking Therapeutics informa que el 74% de los participantes con VK2735 subcutáneo mejoraron de categoría de IMC frente al 15% con placebo después de 13 semanas, con mejoras en los marcadores cardiometabólicos Informado el domingo, Viking Therapeutics informa que el 74% de los participantes con VK2735 subcutáneo mejoraron de categoría de IMC frente al 15% con placebo después de 13 semanas, con mejoras en los marcadores cardiometabólicos Benzinga 2026.11.16 05:21 (GMT+0) Open on Benzinga Other news South Korean Lawmaker Proposes Virtual Asset AML Bill, Exchanges Face Fines of Up to 100 Million Won Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’ Italian Robotics Startup Mosaico Raises €7.5 Million Seed Round Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply Are Wall Street Analysts Bullish on Eversource Energy Stock? Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events
Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’
Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply
Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events